ELZA researchers report 12-month outcomes for a second-generation sub400 cross-linking protocol that extends CXL to ultra-thin keratoconus and post-LASIK ectasia corneas below 400 micrometres, halting progression in 76% of eyes while shortening treatment to about 18 minutes.
Insights from ELZA’s contributions to the World Keratoconus Congress 2026 in Florence – ELZA PACE, CXL innovation, and personalised keratoconus treatment strategies
At the 10th SAoO Congress in Lucerne, Dr. Emilio Torres-Netto examined how advances in keratoconus care may further reduce the need for keratoplasty by 2040
A January 2026 The Ophthalmologist article outlines how personalised CXL is applied in three real-world scenarios: good vision, cataract planning, and markedly irregular corneas.
Emilio Torres-Netto reviewed the evolution of epi-on CXL at KCXL 2025, explaining early failures and how modern protocols now achieve clinically meaningful keratoconus stabilisation.
Auf dem ESCRS 2025 in Kopenhagen präsentierte Dr. Emilio A. Torres-Netto neue Strategien zur Behandlung von Patienten mit Katarakt und Keratokonus – einer besonders anspruchsvollen Kombination.
